동물용 의약품 조제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물 유형별, 투여 경로별, 제형별, 지역별, 부문 예측(2025-2030년)
Animal Drug Compounding Market Size, Share & Trends Analysis Report By Product, By Animal Type, By Route Of Administration, By Dosage Form, By Region, And Segment Forecasts, 2025 - 2030
상품코드:1632578
리서치사:Grand View Research
발행일:2024년 12월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
동물용 의약품 조제 시장의 성장과 동향 :
Grand View Research, Inc.의 최신 보고서에 따르면 세계 동물 조제물 시장 규모는 2030년까지 24억 5,000만 달러에 달할 것으로 예측됩니다.
이 시장은 2025년부터 2030년에 걸쳐 CAGR 8.29%를 나타낼 것으로 예상됩니다. 시장 성장을 가속하는 주요 요인으로는 반려동물의 사육수 증가, 방대한 동물의료지출, 특수의약품에 대한 주인의 의식의 높아짐, 브랜드화된 동물용 의약품의 고비용, 반려동물의 인간화 동향, 맞춤형 동물용 배합약 수요 증가 등이 있습니다.
COVID-19 팬데믹은 몇몇 다른 세계 산업과 마찬가지로 2020년 동물 조제 시장에 부정적인 영향을 미쳤습니다. COVID-19가 동물 의료 시스템에 미치는 가장 큰 영향은 공급망 혼란, 매출 감소, 수요 둔화, 규제 및 정책 변화로 인한 경영 문제입니다. 많은 지역이 주를 들고 봉쇄조치에 들어가 사람이나 물자의 이동에 제한이 부과되었기 때문에 제조회사, 동물용 약국, 동물용 치료 서비스 제공업체는 심각한 영향을 받았습니다. 예를 들어 미국 수의사회에 따르면 2020년 4월에는 코로나바이러스의 발생으로 약 60%의 동물병원이 진료를 중지 또는 연기했으며, 2020년 7월에는 약 30%까지 감소했습니다. 따라서 COVID-19의 영향은 시장 성장을 방해합니다.
동물용 의약품의 제제는 동물용 치료제로 허가된 의약품의 입수가 쉽지 않거나 다른 동물용 의약품의 대체품에 의해 남겨진 갭을 메우는 것입니다. 특정 병리학에 대한 FDA 승인 의약품을 얻기가 어려운 경우, 제형은 다양한 동물의 질병을 치료하는 더 나은 옵션이 될 것입니다. 예를 들어, 씹을 수 있는 정제는 특정 투여 형태로 상업적으로 승인된 제품이며, 특정 동물 종에 대한 사용이 권장되지만, 고양이 또는 이국적인 반려동물과 같은 동물에 대한 사용은 허용되지 않습니다. 마찬가지로, 널리 시판되는 의약품은 동물에 따라 불쾌한 맛을 내기 때문에 복용량이 제한됩니다. 이러한 경우, 특히 투여가 어려운 약물의 경우 동물 조제가 바람직합니다.
팬데믹 기간 동안 반려동물 사육은 상당히 증가했고 동물 의학 인프라 증가로 이어졌으며 동물 제제 시장을 견인했습니다. 2021년 5월 미국 동물학대방지협회(ASPCA)가 발표한 보고서에 따르면 COVID-19의 대유행이 시작된 이래 5세대에 1세대가 고양이와 개를 키우게 되었습니다. 유행 사이의 입양으로 인한 반려동물의 건강에 대한 관심 증가는 앞으로 수년간 동물 조제 시장의 확대를 촉진할 것으로 예상됩니다.
마찬가지로 세계 동물용 의약품 조제 시장은 시장 진출기업이 수의사의 건강에 관한 프로그램이나 이니셔티브에 주력하고 있기 때문에 확대가 전망되고 있습니다. 예를 들어, 2021년 6월, Covetrus는 약 1,000개의 클리닉에 서비스를 제공했으며, 현재 VCP에 의해 활성화된 웰니스 플랜을 통해 35만 개 이상의 반려동물에 이익을 주는 수의사 웰니스 플랜을 관리하기 위한 플랫폼인 VCP를 인수했습니다. Covetrus는 VCP가 제공하는 인프라와 기술 플랫폼을 활용하여 수의사가 반려동물 주인과 보다 긴밀한 관계를 구축하고 비즈니스와 의료 모두에서 더 나은 결과를 창출하는 새로운 방법을 제공합니다.
동물용 의약품 조제 시장 : 분석 개요
동물 유형별로 반려동물 부문은 2024년에 가장 큰 수익 점유율을 차지했습니다. 이는 반려동물 동물의 채용이 증가하고 있는 것, 동물에 대한 지출이 증가하고 있으며, 반려동물 동물용 제제 수요가 증가하고 있기 때문입니다.
제품별로는 중추신경계 약물 부문이 2024년에 약 33% 시장 점유율을 차지했습니다. 중추 신경계 약물은 반려동물의 행동 변화, 실명, 발작, 간질과 같은 신경 증상을 치료하기 위해 가장 자주 처방되는 약물이기 때문입니다. 호르몬제와 대용제는 동물의 호르몬 밸런스 흐트러짐의 치료에 적합하고 보다 강력하기 때문에 9.0% 이상의 비율로 급성장하고 있는 분야입니다.
투여경로 중에서 경구약이 가장 선호되고 간편하고 받아들일 수 있는 약물 투여 경로이기 때문에 경구약 부문은 2024년에 53% 이상의 최대 시장 점유율을 차지했습니다. 한편, 국소 약물은 투여 경로 중 가장 급성장하는 부문이며, 예측 기간 동안의 성장률은 9.0%를 초과하고 있습니다.
제형별로, 현탁액이 동물용으로 가장 많이 제제되는 제형이기 때문에 현탁액 부문은 2024년에 약 49%의 최대의 판매 점유율을 차지했습니다. 용액 부문은 다른 고형 제형에 비해 용액의 몇 가지 장점으로 인해 향후 몇 년 동안 8% 이상의 최고의 CAGR을 나타낼 것으로 추정됩니다. 용액은 보통 고형제보다 흡수가 빠르고 소화관 점막에 친화적입니다. 게다가, 현탁액과는 달리, 용액에서 보존 중 상분리는 문제가 되지 않습니다. 이 때문에 예측 기간 동안 용액 제제의 인기가 높아질 것으로 예상됩니다.
반려동물 사육수 증가, 동물의료비 증가, 동물용 의약품 조제 수요의 높이에서 2024년 지역별 시장 점유율은 북미가 약 40%로 가장 높았습니다. 아시아태평양은 반려동물의 휴머니제이션 증가, 동물 의료 지출 증가, 저비용 동물용 제제의 가용성으로 인해 CAGR 약 10.0%의 가장 빠른 성장이 예상되고 있습니다.
The global animal drug compounding market size is anticipated to reach USD 2.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 8.29% from 2025 to 2030. The key factors driving the market growth include a rise in pet adoption, huge animal healthcare spending, increased pet owner awareness regarding specialty pharmaceuticals, the high cost of branded veterinary products, pet humanization trends, and an increase in the demand for custom-made, compounded animal medications.
The COVID-19 pandemic had a negative impact on the market for animal drug compounding in 2020, just like on several other global industries. The most significant effects of COVID-19 on the veterinary healthcare system are supply chain disruptions, a drop in sales, a slowdown in demand, and operational challenges brought on by shifting regulations and policies. Manufacturing firms, veterinary pharmacies, and animal care service providers were severely impacted as many areas entered state-wide lockdowns and imposed restrictions on the movement of people and goods. For instance, according to the American veterinary medical association, in April 2020, approximately 60% of veterinary practices were canceled or delayed due to the outbreak of coronavirus and in July 2020, the number of veterinary practices declined to about 30%. Thus, the impact of COVID-19 has hampered market growth.
Compounding veterinary drugs fills the gaps left by less readily available licensed drugs for veterinary treatment and other veterinary medication alternatives. Compounded medications are a better choice for treating a wide range of animal diseases when FDA-approved drugs are difficult to find for certain medical conditions. For instance, chewable tablets are commercially approved products in specific dosage forms and are suggested for use in certain animal species yet are unacceptable for use in animals such as cats or exotic pets. Similarly, widely available medications have an unpleasant taste for some animals limiting the administering rate. In this case, animal drug compounding is preferred, particularly for difficult-to-administer medications.
During the pandemic, pet adoption considerably increased, leading to an increased animal healthcare infrastructure and driving the market for compounded medications for animals. According to a report published by the American Society for the Prevention of Cruelty to Animals (ASPCA) in May 2021, one in every five families had adopted a cat or dog since the COVID-19 pandemic began. The increased focus on pet health brought on by adoptions during the pandemic is expected to drive the expansion of the animal drug compounding market over the coming years.
Similarly, the global animal drug compounding market is expected to expand due to market players focusing on programs and initiatives concerning veterinary health. For instance, in June 2021, Covetrus acquired VCP, a platform for administering veterinary wellness plans that serves about 1,000 practices and presently benefits over 350,000 pets through wellness plans that are enabled by VCP. Covetrus will make use of the infrastructure and technology platform provided by VCP to offer new methods for vets to develop closer bonds with their pet owners and produce better results in terms of both business and healthcare.
Animal Drug Compounding Market Report Highlights:
Based on animal type, the companion animals segment accounted for the largest revenue share in 2024. This can be attributed to the increasing adoption of pet animals, the rise in animal expenditure, and the increasing demand for compounding medication for pet animals.
Based on products, the CNS agents segment dominated with a market share of around 33% in 2024, as CNS agents are the most frequently prescribed medication for treating neurological conditions such as changes in behavior, blindness, seizures, epilepsy, etc., in pets. Hormones & Substitutes is the fastest-growing segment with a rate of over 9.0% since it is better and more potent for hormonal imbalance treatment in animals.
Among routes of administration, the oral segment held the largest market share of more than 53 % in 2024, as oral formulations are the preferred, easy, and more acceptable route of drug administration. Whereas, topical is the fastest-growing segment among the routes of administration, with a growth rate of over 9.0% during the forecast period.
Based on dosage form, the suspensions segment accounted for the largest revenue share of about 49% in 2024, as suspensions were the most dispensed compounded dosage form for animals. The Solutions segment is estimated to register the highest CAGR of over 8% in the coming years owing to the several benefits of the solution compared to another solid dosage form. Solutions are usually more GI mucosa-friendly than solid dosage forms as they are more quickly absorbed. In addition, unlike suspensions, phase separation during storing is not an issue with solutions. Thus, solutions are expected to gain popularity during the forecast period.
North America attributed the largest share of about 40% of the market by region in 2024, owing to an increase in pet ownership together with rising animal health expenditure and high demand for animal drug compounding. While Asia pacific is expected to grow at the fastest CAGR of about 10.0% due to an increase in pet humanization, growing animal healthcare expenditure, and the availability of low-cost animal compounding medications.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Animal Type
1.2.3. Route of Administration
1.2.4. Dosage Form
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR's Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Animal Drug Compounding Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter's Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
Chapter 4. Animal Drug Compounding Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Anti-infective Agents
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Anti-inflammatory Agents
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Hormones & Substitutes
4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. CNS Agents
4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Other Products
4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Animal Drug Compounding Market: Animal Type Business Analysis
5.1. Animal Type Market Share, 2024 & 2030
5.2. Animal Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Animal Type, 2018 to 2030 (USD Million)
5.4. Companion Animal
5.4.1. Dogs
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Cats
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Horses
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. Others
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Livestock Animal
5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Animal Drug Compounding Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Injectable
6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Topical
6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Other Routes
6.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Animal Drug Compounding Market: Dosage Form Business Analysis
7.1. Dosage Form Market Share, 2024 & 2030
7.2. Dosage Form Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
7.4. Suspensions
7.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Solutions
7.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Capsules
7.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Animal Drug Compounding Market: Regional Estimates & Trend Analysis by Product, Animal Type, Route of Administration, and Dosage Form
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key country dynamics
8.4.2.2. U.S. animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key country dynamics
8.4.3.2. Canada animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key country dynamics
8.4.4.2. Mexico animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key country dynamics
8.5.2.2. UK animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key country dynamics
8.5.3.2. Germany animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key country dynamics
8.5.4.2. France animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key country dynamics
8.5.5.2. Italy animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key country dynamics
8.5.6.2. Spain animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.7. Norway
8.5.7.1. Key country dynamics
8.5.7.2. Norway animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key country dynamics
8.5.8.2. Denmark animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.9. Sweden
8.5.9.1. Key country dynamics
8.5.9.2. Sweden animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key country dynamics
8.6.2.2. Japan animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key country dynamics
8.6.3.2. China animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key country dynamics
8.6.4.2. India animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key country dynamics
8.6.5.2. South Korea animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key country dynamics
8.6.6.2. Australia animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key country dynamics
8.7.2.2. Brazil animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key country dynamics
8.7.3.2. Argentina animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key country dynamics
8.8.2.2. South Africa animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key country dynamics
8.8.3.2. Saudi Arabia animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key country dynamics
8.8.4.2. UAE animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key country dynamics
8.8.5.2. Kuwait animal drug compounding market estimates and forecasts, 2018 - 2030 (USD Million)
